In both breast cancer cell lines used, MCF-7 and MDA-MB-468, a decrease in LSD1 levels was accompanied by a reduction in the number of cells that survived after doxorubicin administration, while overexpression of the enzyme had the opposite results. The gene discussed is KDM1A; the disease is breast carcinoma.